Abstract Sclerostin negatively regulates bone formation. The marketed antibody against sclerostin loop2 promoted bone formation but may have caused severe cardiovascular events in clinical use. In our published studies, sclerostin loop3 was found to be involved in inhibitory effects of sclerostin on bone formation, whereas cardiovascular protective effects of sclerostin in mice were independent of loop3.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Péter Ferdinandy
Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy
Abstract The aim of this study was to elucidate cardiovascular prescriber access, uptake, and attitudes toward CYP2C19 and CYP2D6 genetic testing to guide prescribing of commonly used medications such as clopidogrel, antiarrhythmics, proton pump inhibitors, and antidepressants. A survey, designed in collaboration with the European Society of Cardiology (ESC) WG on Cardiovascular Pharmacotherapy and external experts was disseminated to ESC members using SurveyMonkey.
Response to: Justifying and reporting the use of severe stress in experiments that use animals
Article Dans Une Revue British Journal of Pharmacology Année : 2026 Response to: Justifying and reporting the use of severe stress in experiments that use animals Domaines Fichier principal British J Pharmacology - 2026 - Ferdinandy - Response to Justifying and reporting the use of severe stress in experiments.pdf (663.08 Ko) Télécharger le fichier Origine Fichiers produits par l'(les) auteur(s) Licence
Response to: Justifying and reporting the use of severe stress in experiments that use animals
We thank Stanford et al. for their careful attention to an important matter (Stanford et al., 2026). As the substantive points in the letter relate to the validity of the procedure reported, the authors of the original article (Michael et al., 2025) have provided a detailed scientific response, published alongside the letter. As a few points in the letter relate to editorial procedure, it is helpful for the Journal to also respond.
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
ASCO American Society of Clinical Oncology BSA body surface area CRC colorectal carcinoma CSs corticosteroids CTCAE Common Terminology Criteria for Adverse Events CTLA-4 cytotoxic T lymphocyte-associated antigen 4 DM diabetes mellitus ESCC oesophageal squamous cell carcinoma ESMO European Society for Medical Oncology HCC hepatocellular carcinoma HL Hodgkin's lymphoma HNSCC head and neck squamous cell carcinoma ICI immune checkpoint inhibitor IFX infliximab irAEs immune-related adverse events...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Péter
Contact Péter, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack